Prediction and decision-making based on nonlinear risks model in stomach cancer treatment
https://doi.org/10.37661/1816-0301-2024-21-1-65-82
Abstract
Objectives. The goals are to develop a nonlinear risk model and examine its prediction applicability for clinical use.
Methods. Methods of survival analysis and regression statistical models were used.
Results. A practical approach to assessing nonlinear risks of adverse events using the example of gastric cancer treatment is proposed. A model for predicting the metachronous peritoneal dissemination in patients undergoing radical surgery for gastric cancer was proposed and studied. Assessment of risks for various periods of observation was performed, and the clinical suitability of developed approach was assessed.
Conclusion. In clinical oncological practice, not only timely treatment plays an important role, but also the prevention of adverse outcomes after treatment. Individualization of patient monitoring after treatment reduces the risks of fatal outcomes and the costs of additional research and treatment in the event of cancer progression. Based on the results of this study, we propose solutions that should lead to more effective and high-quality treatment tactics and follow-up after treatment for gastric cancer, also to the selection of optimal approaches and to obtaining clinically favorable outcomes of the disease. The proposed risk prediction method will ultimately lead to individualized patient management based on the results of personal data.
About the Authors
O. V. Krasko
The United Institute of Informatics Problems of the National Academy of Sciences of Belarus
Belarus
Belarus
Olga V. Krasko, Ph. D. (Eng.), Assoc. Prof., Leading Researcher
st. Surganova, 6, Minsk, 220012
M. Yu. Reutovich
Belarusian State Medical University
Belarus
Belarus
Mikhail Yu. Reutovich, D. Sc. (Med.), Assoc. Prof., Dean of the Faculty of General Medicine
av. Dzerzhinsky, 83, Minsk, 220083
A. V. Ivanov
N. N. Alexandrov National Cancer Center of Belarus
Belarus
Belarus
Andrey V. Ivanov, Postgraduate Student
Lesnoy, Minsk Region, 223040
References
1. Alonzo T. A. Clinical prediction models: a practical approach to development, validation, and updating: by Ewout W. Steyerberg. – 2009.]
2. O'Mahony C. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD) //European heart journal. – 2014. – Т. 35. – №. 30. – С. 2010-2020]
3. Scrucca L., Santucci A., Aversa F. Competing risk analysis using R: an easy guide for clinicians //Bone marrow transplantation. – 2007. – Т. 40. – №. 4. – С. 381-387.
4. Wolbers M. et al. Prognostic models with competing risks: methods and application to coronary risk prediction //Epidemiology. – 2009. – С. 555-561.
5. Cox D. R. Regression models and life‐tables //Journal of the Royal Statistical Society: Series B (Methodological). – 1972. – Т. 34. – №. 2. – С. 187-202.
6. Hosmer Jr D. W., Lemeshow S., May S. Applied survival analysis: regression modeling of time-to-event data. – John Wiley & Sons, 2011. – Т. 618.
7. Therneau T., Crowson C., Atkinson E. Using time dependent covariates and time dependent coefficients in the cox model //Survival Vignettes. – 2017. – Т. 2. – №. 3. – С. 1-25.
8. Murphy S. A., Sen P. K. Time-dependent coefficients in a Cox-type regression model //Stochastic Processes and their Applications. – 1991. – Т. 39. – №. 1. – С. 153-180.
9. Thomas L., Reyes E. M. Tutorial: survival estimation for Cox regression models with time-varying coefficients using SAS and R //Journal of Statistical Software. – 2014. – Т. 61. – С. 1-23.
10. Redmond C., Fisher B., Wieand H. S. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival //Cancer Treatment Reports. – 1983. – Т. 67. – №. 6. – С. 519-526.
11. Suissa S. Immortal time bias in pharmacoepidemiology //American journal of epidemiology. – 2008. – Т. 167. – №. 4. – С. 492-499.
12. Fine J. P., Gray R. J. A proportional hazards model for the subdistribution of a competing risk //Journal of the American statistical association. – 1999. – Т. 94. – №. 446. – С. 496-509.
13. Li J., Scheike T. H., Zhang M. J. Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals //Lifetime data analysis. – 2015. – Т. 21. – №. 2. – С. 197-217.
14. Agnes A. et al. A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer //Journal of Surgical Oncology. – 2020. – Т. 122. – №. 2. – С. 293-305.
15. Seyfried F. et al. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin–a longitudinal experience from a prospectively collected database of 1108 patients //BMC cancer. – 2015. – Т. 15. – С. 1-10.
16. Lee J. H. et al. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma //Annals of surgery. – 2018. – Т. 267. – №. 1. – С. 105.
17. Reutovich M.Y, Krasko O.V, Sukonko O.G. Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. J Gastrointest Oncol 2021;12(Suppl 1):S5-S17. doi: 10.21037/jgo-20-129.
18. Chen X. et al. Analysis and external validation of a nomogram to predict peritoneal dissemination in gastric cancer //Chinese Journal of Cancer Research. – 2020. – Т. 32. – №. 2. – С. 197-207.
19. Dromain C. et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT //Abdominal imaging. – 2008. – Т. 33. – С. 87-93.
20. Kawanaka Y. et al. Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer: comparison with contrast-enhanced MDCT //European journal of radiology. – 2016. – Т. 85. – №. 5. – С. 989-995.
21. Wu F. et al. Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases //Oncotarget. – 2017. – Т. 8. – №. 44. – С. 78120.
22. Locally advanced gastric cancer: modern directions of radical treatment and prediction of long-term results: monograph / Reutovich M.Yu., Krasko O.V.. – Minsk: Belarusian Medical Academy of Postgraduate Education, 2022. – 217 p.
23. Results of radical treatment of infiltrative gastric cancer using perfusion thermochemotherapy / Reutovich M.Yu., Krasko O.V., Malkevich V.T., Patseika A.I. // Eurasian Journal of Oncology. – 2022, – Vol. 10, №2, – P. 107-117.
24. Reutovich M.Yu., Krasko O.V. Intraoperative risk assessment of carcinomatosis development after radical surgery for gastric cancer// Oncology and Radiology of Kazakhstan, N2 (56) 2020. DOI: 10.52532/2521-6414-2020-2-56-26-30.
25. Reutovich M., Krasko O. Prophylactic hyperthermic intraperitoneal chemotherapy in gastric cancer management: short- and long-term outcomes of a prospective randomized study // Oncology in clinical practice . 2021, Vol. 17, № 5, – p. 187–193. DOI: 10.5603/OCP.2021.0028.
26. M. Yu Reutovich, O.V.Krasko, O.G.Sukonko: Efficacy of Adjuvant Systemic Chemotherapy Combined with Radical Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer Treatment // Indian Journal of Surgical Oncology. 2020. –Vol. 11. P. 337-343. https://doi.org/10.1007/s13193-020-01102-w.
27. Алгоритмы диагностики и лечения злокачественных новообразований: клинический протокол: утв. Постановлением М-ва здравоохранения Респ. Беларусь № 60 от 06.07.2018 г. / под ред. О. Г. Суконко, С. А. Красного. – Минск: Профессиональные издания, 2019. – С. 97–110.
28. Schoenfeld D. Partial residuals for the proportional hazards regression model //Biometrika. – 1982. – Т. 69. – №. 1. – С. 239-241.
29. Harrell F. E. et al. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. – New York : Springer, 2001. – Т. 608.
30. Heagerty P. J., Lumley T., Pepe M. S. Time‐dependent ROC curves for censored survival data and a diagnostic marker //Biometrics. – 2000. – Т. 56. – №. 2. – С. 337-344.
31. Steyerberg E. W. A practical approach to development, validation, and updating //Clinical Prediction Models. – 2009.
32. Vickers A. J., Elkin E. B. Decision curve analysis: a novel method for evaluating prediction models //Medical Decision Making. – 2006. – Т. 26. – №. 6. – С. 565-574.
33. Vickers A. J., Van Calster B., Steyerberg E. W. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests //bmj. – 2016. – Т. 352.
34. Vickers A. J. et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers //BMC medical informatics and decision making. – 2008. – Т. 8. – С. 1-17.
Review
For citations:
Krasko O.V., Reutovich M.Yu., Ivanov A.V. Prediction and decision-making based on nonlinear risks model in stomach cancer treatment. Informatics. 2024;21(1):65-82. (In Russ.) https://doi.org/10.37661/1816-0301-2024-21-1-65-82
Views: 116
Email this article 